Milestones

ITI has already achieved numerous milestones in areas including research and development, intellectual property, delivery systems and manufacturing:

• ITI currently has two lead products in active clinical stage development:
  • hydromorphone for acute, moderate-to-severe pain (Phase II),
  • midazolam for epileptic seizure (Phase I)
• Nineteen clinical trials have been performed
  successfully to date.
• Multiple other compounds that lend themselves well to nasal delivery are under evaluation or in preclinical development.
• Preservative-free formulations have been developed, improving patient comfort and convenience by eliminating irritating and potentially toxic preservatives.
• ITI has an ongoing working relationship with the
  University of Kentucky College of Pharmacy, a top
  ten U.S. pharmacy school and a pioneer in nasal
  drug delivery, to conceptualize and develop nasal
  drug formulations.
• Multiple issued patents and pending applications.
• ITI has an established proprietary manufacturing
  facility believed to be the only U.S. facility with aseptic filling, assembling and packaging capability for preservative- free nasal drug products.